InnoCare Advances Phase III AML Trial of Mesutoclax
BEIJING, August 18, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products...
venetoclax
Advertisement
Actinium Advances Actimab-A With Manufacturing Expansion
New York, United States, August 14, 2026 Actinium Pharmaceuticals, Inc. announced new intellectual property and manufacturing developments supporting its...
Moleculin Reports Positive Interim MIRACLE Trial Data in Venetoclax-Failed AML Patients
HOUSTON, July 31, 2026 Moleculin Biotech, Inc. announced updated positive preliminary blinded interim results from Part A of its...
AB Science Prioritizes AML and ALS Programs
PARIS, July 10, 2026 AB Science announced a major strategic update to its clinical development pipeline, confirming that it...
AbbVie Reports 9-Year VENCLEXTA Data in First-Line CLL
NORTH CHICAGO, Ill., June 12, 2026 AbbVie announced new long-term clinical results from the Phase 3 CLL14 trial at...
Advertisements
AbbVie Secures EU Approval for Expanded VENCLYXTO Use in First-Line CLL
NORTH CHICAGO, Ill., May 29, 2026 AbbVie announced that the European Commission (EC) has approved an expanded label for...
Akeso Reports Positive Phase II Ligufalimab AML Data at EHA 2026
HONG KONG, May 15, 2026 Akeso, Inc. announced positive Phase II clinical trial results for ligufalimab (AK117) in frontline...
Taiho Oncology Wins FDA Approval for INQOVI Combo
PRINCETON, N.J. and TOKYO, May 13, 2026 Taiho Oncology and Taiho Pharmaceutical announced that the U.S. Food and Drug...
Aptose to Present Promising Tuspetinib AML Data at 2025 ASH Meeting
SAN DIEGO and TORONTO, November 3, 2025 — Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, announced...
Advertisement
